ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) Rockets Higher on Medical Milestone


ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) rocketed upward today and closed over 82% on breakthrough news regarding their immunotherapy technology. The milestone the company achieved has spurred investor confidence and given them a proof-of-concept path forward.

“We are excited to have achieved this critical initial milestone in our Stem-to-T-Cell program, and to have generated a body of scientific evidence of successful transfection and proof that the transfected human hematopoietic stem cells bearing the TCR were able to grow robustly for several generations,” said Steven J. Swanson, PhD, Senior Vice President, Research. “We and our collaborators are on schedule to undertake next anticipated steps designed to enhance the transfection process and advance toward preclinical testing. We remain committed to our vision to develop solutions for intractable cancers, extending the lives of cancer patients, and providing hope for a potential cure. We believe that our Stem-to-T-Cell program is potentially a game-changing treatment for cancer.”

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Find out when $IMUC stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Based on the technology in-licensed from The California Institute of Technology in 2014 ImmunoCellular’s Stem-to-T-Cell program is designed to harness the power of the immune system in highly directed and specific ways to engineer highly antigen-specific tumor killing. At the core of the Stem-to-T-Cell technology is harvesting stem cells from cancer patients and then cloning into them T cell receptors that are specific for cancer cells. These engineered stem cells can then be reintroduced into the patient and are pre-programed to produce daughter cells that are antigen specific killer T cells that are capable of identifying, binding to, and killing cancer cells. Because stem cells are immortal, these reengineered stem cells could provide a natural and perpetual source of T cells that can target and destroy cancer cells in the patient.

According to the news release, the Stem-to-T-Cell platform has the potential to address many types of cancer, including both solid and hematological tumors and has the potential to result in a potentially curative therapy for many different types of cancers. The stem cell platform represents a novel and more direct approach to generating killer T cells by using the patient’s stem cells as starting material.  Thus, ImmunoCellular’s Stem-to-T-Cell technology shares some similarities with other immuno-oncology technologies, such as CAR-T, and could potentially be used in combination approaches.

Anthony J. Gringeri, PhD, President and CEO commented: “We are proud of the achievements of our research team and the important scientific validation of our Stem-to-T-Cell program generated to date. We believe that our stem cell technology represents a major step forward in immuno-oncology, and has the potential for meaningful advantages over other novel immuno-oncology technologies, including use in combination approaches. With our strengthened financial condition and cash reserves, we intend to continue to focus our resources on achieving additional research milestones over the next 18 months. We are also continuing to explore potential collaborations for our clinical programs and other strategic alternatives for our Company.”

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) has a $9.59M market cap and 23.79M shares out. IMUC will certainly be offering updates on the path forward and additional testing as this operation goes forward. We will be writing more updates soon. Sign-up for continuing coverage on shares of $IMUC stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $IMUC, either long or short, and we have not been compensated for this article.